Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma.

• DOI: 10.1200/jco.2024.42.16_suppl.6090
• Publication Date: 2024-07-08T18:29:11Z
• Authors: Lei Liu; Yi Li; Chunjie Li; Xiang Xz; Zhuoyuan Zhang; Huixu Xie; Yueyang Tang; Bowen Zhang; Chenfeng Tan; Guile Zhao; Yuanyuan Zeng; Jun Wang; Wenju Xiong; Mingmin He
• Keywords: Neoadjuvant Therapy; Oral Cancers

6090 Background: The effectiveness of neoadjuvant immunochemotherapy (NAIC) in treating resectable locally advanced oral squamous cell carcinoma (LAOSCC) remains uncertain, with a notable lack precise prognostic markers for NAIC outcomes. Methods: A single-arm prospective phase II trial was performed to assess the efficacy and safety NAIC, consisting 2 cycles intravenous camrelizumab (200 mg), albumin paclitaxel (260 mg/m²), cisplatin (75 mg/m²) administered every 3 weeks prior radical surgery LAOSCC patients. Adjuvant radiotherapy or chemoradiotherapy determined by post-surgical pathology. Patients previously untreated, stage III-IVB (the 8th edition UICC/AJCC staging system), aged 18-75 years were enrolled. primary endpoints major pathological response (MPR, defined as ≤10% residual viable tumour (%RVT) cells) safety, second point objective rate (ORR) according RECIST 1.1. To identify potential radiomic predictive benefit, oscillating-gradient spin-echo (OGSE) magnetic resonance imaging sequences obtained before after NAIC. Results: From Feb 1, 2023 Jan 2024, 30 patients enrolled, among which, 26 have received followed surgery. MPR 65.4% (17/26), including 34.6% (9/26) complete response. PD-L1 (Combined Positive Score) ≥ 1 had higher (80.0%, 16/20) than those < (16.7%, 1/6). well-tolerated, without adverse effects on subsequent surgery, only two experienced grade 4 events during one neutropenia (3.8%), thrombocytopenia (3.8%). ORR 80.8% (21/26), 15.4% (4/26) response, (17/26) partial no cases progressive disease observed. mean diameters whole tumor calculated based OGSE sequences, twenty completed scaning pre- post-NAIC treatment. Pearson correlation analyses found that small diameter significantly related fewer %RVT ( p = 0.026), supporting its new predictors efficacy. Among MPR, decreased 18.87 ± 2.49 μm 14.77 1.85 tumor, respectively 0.001). Conclusions: Camrelizumab combined paclitaxel/cisplatin demonstrates promising well safety. Mean derived from emerges marker predicting Ongoing follow-ups long-term survival development bio-radiomic prediction model integrating features data are underway. Clinical information: ChiCTR2200066119.